Top Page
Burcon Nutrascience
(TSX:BU)
Burcon Nutrascience (BU) vs. iShares MSCI Canada ETF (EWC)
Burcon Nutrascience Business Overview & Revenue Model
Burcon Nutrascience Earnings Call Summary
Burcon Nutrascience Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 381.40K | 184.36K | 363.91K | 171.47K | 258.65K |
| Gross Profit | -870.76K | 184.36K | 363.91K | 171.47K | -527.31K |
| EBITDA | -7.43M | -6.23M | -18.90M | -9.92M | -4.73M |
| Net Income | -8.26M | -7.45M | -25.36M | -10.26M | -617.49K |
Balance Sheet | |||||
| Total Assets | 30.66M | 12.91M | 9.90M | 29.35M | 37.72M |
| Cash, Cash Equivalents and Short-Term Investments | 7.28M | 4.20M | 1.46M | 7.00M | 13.97M |
| Total Debt | 22.40M | 6.67M | 5.17M | 73.14K | 33.70K |
| Total Liabilities | 23.71M | 7.76M | 5.76M | 1.10M | 1.45M |
| Stockholders Equity | 6.94M | 5.15M | 4.14M | 28.25M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -5.82M | -5.90M | -6.38M | -7.18M | -5.91M |
| Operating Cash Flow | -5.51M | -5.78M | -6.02M | -5.91M | -3.03M |
| Investing Cash Flow | -1.66M | -39.49K | -4.43M | -1.23M | -2.72M |
| Financing Cash Flow | 10.23M | 8.56M | 4.90M | 174.08K | 4.70M |
Burcon Nutrascience Technical Analysis
Burcon Nutrascience Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
| ― | $28.80M | ― | -273.28% | ― | 15.68% | -10.62% | |
| ― | C$5.61M | ― | -2576.83% | ― | -22.92% | 39.22% | |
| ― | C$11.99M | ― | ― | ― | 64.79% | 72.95% | |
| ― | C$5.45M | -2.64 | -89.04% | ― | -49.04% | 14.85% | |
| ― | C$240.41M | -108.70 | ― | ― | 30.02% | 35.29% |
Burcon Nutrascience Corporate Events
Burcon NutraScience Corporation announced that a study by the University of Guelph demonstrated their Peazazz®C pea protein and Solatein™ sunflower protein significantly outperform a leading competitor’s pea protein in plant-based cheese applications. This achievement marks a significant advancement in plant-based cheese production, offering dairy-like melt and stretch properties, and opens new commercial opportunities in the growing dairy-alternative market.
The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.
Burcon NutraScience Corporation has announced its first commercial sales of Puratein®C, a high-purity canola protein isolate with over 90% protein content. This milestone is a significant step in Burcon’s strategy to establish recurring revenue and expand its market reach across high-growth product categories. Puratein C, derived from non-GMO, North American-grown canola seeds, is designed to meet the increasing demand for clean-label, nutritionally complete plant proteins. Its versatility makes it suitable for a wide range of food and beverage applications, reinforcing Burcon’s commitment to delivering sustainable protein solutions.
Burcon NutraScience Corporation has achieved a significant milestone with the first commercial production of Puratein®C, a high-purity canola protein isolate, at its Galesburg facility. This development marks a crucial step in Burcon’s strategy to expand its plant protein portfolio and scale revenue, addressing the increasing global demand for sustainable protein solutions. Puratein®C, derived from non-GMO North American-grown canola seeds, boasts over 90% protein content and a complete amino acid profile, making it ideal for a variety of food and beverage applications. This advancement not only demonstrates Burcon’s capability to scale its innovations but also positions the company to create new revenue streams and enhance its market opportunities.
Burcon NutraScience Corporation announced details of its upcoming annual shareholder meeting, which will be held virtually on September 17, 2025. The company is on track to meet its 2025/2026 milestones, with over 150 active customer projects nearing final evaluation, indicating a strong potential for recurring revenue and rapid scaling. A key agenda item for the meeting is the proposal to amend the exercise price of outstanding warrants to $3.50 per share, which requires shareholder approval. This amendment is seen as beneficial for the company and its shareholders, potentially impacting Burcon’s financial strategies and shareholder value.
The recent earnings call for Burcon NutraScience Corporation was marked by an optimistic tone, underscoring significant advancements in production capabilities, customer engagement, and strategic agreements. Despite some concerns regarding onetime start-up costs, the overall sentiment was positive, with a strong focus on execution and future growth potential.
Burcon NutraScience Corporation is a global leader in plant-based protein innovation, focusing on developing high-performance proteins for the food and beverage industry. The company is known for its extensive patent portfolio and commitment to sustainability.
Burcon NutraScience announced its fiscal 2026 first-quarter results, highlighting a significant phase of growth as it transitions from a technology pioneer to a revenue-generating leader in plant protein innovation. The company achieved key operational milestones, including the first commercial production of Peazazz® C and FavaPro™ proteins at its Galesburg facility, and secured a $6.8 million multi-year production agreement. Despite reporting a net loss of $3.5 million, Burcon’s revenue increased by 44% compared to the previous year, driven by initial protein sales and contract manufacturing services. The company’s participation in the 2025 IFT FIRST Annual Event & Expo generated strong customer interest, positioning Burcon for future revenue growth and long-term shareholder value.
Burcon NutraScience Corporation has announced the appointment of Ms. Alex Varty as the Interim Chief Financial Officer, succeeding Mr. Robert Peets. Ms. Varty, who joined the company in 2024, brings extensive experience in finance and accounting, having previously worked at KPMG LLP. This leadership transition is expected to support Burcon’s ongoing commercial phase and its positioning as a revenue-generating innovation company. The change reflects Burcon’s strategic focus on strengthening its financial operations to enhance its market position in the plant-based protein industry.
Burcon NutraScience Corporation has announced the successful commercial production and launch of FavaPro™, a 90%+ high-purity fava protein isolate. This development is a significant milestone in the company’s growth strategy, enhancing its position as an innovation leader in the plant protein market. FavaPro is designed to meet the increasing demand for healthy and sustainable protein alternatives, offering a neutral flavor profile and hypoallergenic properties, making it suitable for a wide range of food and beverage applications. The launch of FavaPro demonstrates Burcon’s ability to efficiently scale production and diversify its product offerings, addressing the needs of eco-conscious consumers and food formulators.